Frederick Albano, NP
Adult Health · Riverhead, NYNPI 1548694011
Payments from drug & device makers
Across 234 payments — averaging $34.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Cequr Corporation$870
- Mannkind Corporation$550
- Xeris Pharmaceuticals, Inc.$513
- Lilly USA, LLC$496
- Medtronic$467
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,032100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $1,704 |
| Cequr Corporation | 3 | $870 |
| Mannkind Corporation | 18 | $550 |
| Xeris Pharmaceuticals, Inc. | 22 | $513 |
| Lilly USA, LLC | 20 | $496 |
| Medtronic | 26 | $467 |
| Dexcom, Inc. | 6 | $374 |
| AbbVie | 18 | $354 |
| Bayer | 10 | $306 |
| Novo Nordisk | 13 | $249 |
| Abbott | 11 | $192 |
| Sanofi-aventis U.S. LLC | 10 | $191 |
| Amneal Pharmaceuticals LLC | 11 | $182 |
| Insulet Corporation | 5 | $172 |
| Corcept Therapeutics | 8 | $162 |
| Intuity Medical Inc | 2 | $148 |
| Intra-sana Laboratories | 1 | $142 |
| Ascendis Pharma Endocrinology Inc | 1 | $124 |
| Boehringer Ingelheim | 4 | $104 |
| Amgen(2 entities) | 6 | $103 |
| Amarin Pharma, Inc. | 5 | $103 |
| Recordati_rare_diseases_inc. | 4 | $97 |
| Radius Health, Inc. | 5 | $88 |
| Tolmar, Inc. | 1 | $86 |
| Tandem Diabetes Care, Inc. | 4 | $64 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Clarus Therapeutics Inc. | 2 | $38 |
| GSK | 2 | $35 |
| Vivus LLC | 1 | $26 |
| Antares Pharma, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,680
- CeQur Simplicity$870
- LOKELMA$653
- DEXCOM G6 TRANSMITTER$234
- AFREZZA$225
- GLYCATE$142
- Reltone 400 Mg$142
- Reltone 200 Mg$142
- Yorvipath$124
- Kerendia$123
- Pogo Automatic Blood Glucose Monitoring System$122
- RECORLEV$118
How this compares
$8,056 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 291 | $571,990 |
| TrulicityDulaglutide | 262 | $514,529 |
| MounjaroTirzepatide | 217 | $389,965 |
| FarxigaDapagliflozin Propanediol | 196 | $267,647 |
| JardianceEmpagliflozin | 186 | $225,578 |
| JanuviaSitagliptin Phosphate | 174 | $220,833 |
| TradjentaLinagliptin | 114 | $130,505 |
| Bydureon BciseExenatide Microspheres | 40 | $84,442 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 111 | $78,190 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $76,811 |
| RybelsusSemaglutide | 47 | $68,469 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 61 | $62,598 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $38,725 |
| VascepaIcosapent Ethyl | 43 | $34,553 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 181 | $34,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $496 | $911,750507 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $249 | $653,289364 claims |
| Boehringer IngelheimJardiance, Tradjenta | $104 | $356,083300 claims |
| AstraZenecaFarxiga | $1,704 | $267,647196 claims |
| AmgenProlia | $103 | $24,61214 claims |
| AbbVieSynthroid | $354 | $24,175299 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $182 | $9,686716 claims |
| Sanofi-aventis U.S. LLCLantus | $191 | $3,94132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Riverhead
- Frank AlbanoRiverhead$37K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.